<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="abstract" dtd-version="1.0" xml:lang="en" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CC</journal-id>
<journal-id journal-id-type="nlm-ta">Cardiol Croat</journal-id>
<journal-title-group>
<journal-title>Cardiologia Croatica</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Cardiol. Croat.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">1848-543X</issn>
<issn pub-type="epub">1848-5448</issn>
<publisher><publisher-name>Croatian Cardiac Society</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">CC_13(11-12)_448</article-id>
<article-id pub-id-type="doi">10.15836/ccar2018.448</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Extended Abstract</subject></subj-group>
</article-categories>
<title-group>
<article-title>A single-center experience in treating venous thromboembolism: a prospective observational study in a one-year period</article-title>
<trans-title-group xml:lang="HR">
<trans-title>Iskustvo jednog centra u lije&#x010D;enju venske tromboembolije kroz godinu dana: prospektivna opservacijska studija</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6035-6760</contrib-id><name><surname>Mari&#x010D;i&#x0107;</surname><given-names>Lana</given-names></name><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3246-4056</contrib-id><name><surname>Mlinarevi&#x0107;</surname><given-names>Dra&#x017E;en</given-names></name></contrib>
<aff id="aff1">Klini&#x010D;ki bolni&#x010D;ki centar Osijek, Osijek, Hrvatska</aff>
<aff id="aff2"><institution>University Hospital Centre Osijek</institution>, <addr-line>Osijek</addr-line>, <country>Croatia</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>*</label>ADDRESS FOR CORRESPONDENCE: Lana Mari&#x010D;i&#x0107;, Klini&#x010D;ki bolni&#x010D;ki centar Osijek, J. Huttlera 4, HR-31000 Osijek, Croatia. / Phone: +385-98-9359-695 / E-mail: <email xlink:href="dr.lmaricic@gmail.com">dr.lmaricic@gmail.com</email></corresp></author-notes>
<pub-date pub-type="epub-ppub"><month>11</month><year>2018</year></pub-date>
<volume>13</volume>
<issue>11-12</issue>
<fpage>448</fpage>
<lpage>448</lpage>
<history>
<date date-type="received"><day>19</day><month>10</month><year>2018</year></date><date><day>05</day><month>11</month><year>2018</year></date>
</history>
<permissions>
<copyright-year>2018</copyright-year>
<copyright-holder>Croatian Cardiac Society</copyright-holder>
</permissions>
<kwd-group kwd-group-type="translator" xml:lang="HR"><kwd>KLJU&#x010C;NE RIJE&#x010C;I: plu&#x0107;na embolija</kwd><kwd>duboka venska tromboza</kwd><kwd>antikoagulantna terapija</kwd></kwd-group>
<kwd-group kwd-group-type="author"><title>KEYWORDS: </title><kwd>pulmonary embolism</kwd><kwd>deep vein thrombosis</kwd><kwd>anticoagulants</kwd></kwd-group>
</article-meta>
</front>
<body>
<p>Venous thromboembolism represents a significant public health issue &#x2013; it is the third most common cardiovascular disease in Europe. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>-<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) In University Hospital Centre Osijek we admitted a total of 193 patients for venous thromboembolism. We diagnosed deep vein thrombosis in 51.3% and pulmonary embolism in 48.7% of those patients. The average age of patients was 65.5 years, 46.6% were male and 53.4% were female. A recurrent venous thromboembolism was present in 8.8% of patients, and 21.2% had a previously diagnosed malignancy. The most common comorbidity was arterial hypertension. During the hospitalization patients were treated with low-molecular weight heparin. We discharged 48.2% of the patients on direct oral anticoagulants, 26.9% on warfarin and 23.3% on low-molecular weight heparin. Since venous thromboembolism is one of the leading causes of cardiovascular mortality, the aim of this study was to compare clinical practice data from our center with data from previously published international registries. After examining the results, we can conclude that there are many similarities and some differences between patients in our cohort and those from other registries. Since there is no objective data (national registry) available in Croatia, we wish to present the current clinical information about patients with venous thromboembolism in our center and explore questions about the situation in other centers and regions.</p>
</body>
<back>
<ref-list>
<title>LITERATURE</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tzoran</surname><given-names>I</given-names></name><name><surname>Brenner</surname><given-names>B</given-names></name><name><surname>Papadakis</surname><given-names>M</given-names></name><name><surname>Di Micco</surname><given-names>P</given-names></name><name><surname>Monreal</surname><given-names>M</given-names></name></person-group>. <article-title>VTE Registry: What Can Be Learned from RIETE?</article-title> <source>Rambam Maimonides Med J</source>. <year>2014</year> Oct 29;<volume>5</volume>(<issue>4</issue>):<fpage>e0037</fpage>. <pub-id pub-id-type="doi">10.5041/RMMJ.10171</pub-id><pub-id pub-id-type="pmid">25386353</pub-id></mixed-citation></ref>
<ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weitz</surname><given-names>JI</given-names></name><name><surname>Haas</surname><given-names>S</given-names></name><name><surname>Ageno</surname><given-names>W</given-names></name><name><surname>Angchaisuksiri</surname><given-names>P</given-names></name><name><surname>Bounameaux</surname><given-names>H</given-names></name><name><surname>Nielsen</surname><given-names>JD</given-names></name><etal/></person-group> <article-title>Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design.</article-title> <source>Thromb Haemost</source>. <year>2016</year> Nov 30;<volume>116</volume>(<issue>6</issue>):<fpage>1172</fpage>&#x2013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1160/TH16-04-0335</pub-id><pub-id pub-id-type="pmid">27656711</pub-id></mixed-citation></ref>
<ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agnelli</surname><given-names>G</given-names></name><name><surname>Verso</surname><given-names>M</given-names></name><name><surname>Ageno</surname><given-names>W</given-names></name><name><surname>Imberti</surname><given-names>D</given-names></name><name><surname>Moia</surname><given-names>M</given-names></name><name><surname>Palareti</surname><given-names>G</given-names></name><etal/><collab>MASTER investigators</collab></person-group>. <article-title>The MASTER registry on venous thromboembolism: description of the study cohort.</article-title> <source>Thromb Res</source>. <year>2008</year>;<volume>121</volume>(<issue>5</issue>):<fpage>605</fpage>&#x2013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.thromres.2007.06.009</pub-id><pub-id pub-id-type="pmid">17692901</pub-id></mixed-citation></ref>
</ref-list>
</back>
</article>
